Design of a Phase III immunogenicity and safety study evaluating two-dose regimens of 9-valent human papillomavirus (9vHPV) vaccine with extended dosing intervals-Reference-Cited by-同舟云学术

Design of a Phase III immunogenicity and safety study evaluating two-dose regimens of 9-valent human papillomavirus (9vHPV) vaccine with extended dosing intervals

Published:2021-06 Issue: Volume:105 Page:106403
ISSN:1551-7144
Container-title:Contemporary Clinical Trials
language:en
Short-container-title:Contemporary Clinical Trials

Author:

Teppler Hedy,Bautista Oliver,Flores Sheryl,McCauley Jennifer,Luxembourg Alain

Publisher

Elsevier BV

Subject

Pharmacology (medical),General Medicine

Reference36 articles.

1. 9-valent human papillomavirus vaccine: a review of the clinical development program;Luxembourg;Expert. Rev. Vaccines,2017

2. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study;de Sanjose;Lancet Oncol.,2010

3. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine;Garland;J. Infect. Dis.,2009

4. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide;Alemany;Int. J. Cancer,2015

5. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease;Serrano;Infect. Agent. Cancer,2012

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV Vaccine;Pediatrics;2024-07-09

2. Meeting Summary: Global Vaccine and Immunization Research Forum, 2021;Vaccine;2023-03

3. Human papillomavirus (HPV) vaccines in adults: Learnings from long-term follow-up of quadrivalent HPV vaccine clinical trials;Human Vaccines & Immunotherapeutics;2023-01-02